Open Access

Comprehensive analysis of expression profiles of long non‑coding RNAs with associated ceRNA network involved in gastric cancer progression

  • Authors:
    • Wei Gu
    • Jia‑Hui Ren
    • Xiong Zheng
    • Xiao‑Ying Hu
    • Mei‑Jie Hu
  • View Affiliations

  • Published online on: July 9, 2019     https://doi.org/10.3892/mmr.2019.10478
  • Pages: 2209-2218
  • Copyright: © Gu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Long non‑coding RNAs (lncRNAs) play critical roles in the development and progression of cancers. The present study aimed to identify novel lncRNAs and associated microRNAs (miRNAs or miRs) and mRNAs in gastric cancer. Differentially expressed lncRNAs (DElncRNAs) and differentially expressed mRNAs (DEmRNAs) of 6 paired gastric cancer and normal tissues were identified using microarray. The DEmiRNAs between gastric cancer and the normal control tissues were identified using miRNA‑seq data from Cancer Genome Atlas. Common DElncRNAs from the Cancer RNA‑Seq Nexus database and circlncRNAnet database were analyzed. A DElncRNAs‑DEmiRNAs‑DEmRNAs network was constructed by target prediction. Functional enrichment analysis was employed to predict the function of DEmRNAs in the network. The correlation between the expression of DElncRNAS and DEmRNAs in the network was analyzed. The expression levels of several genes were validated by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). A total of 1,297 DElncRNAs, 2,037 DEmRNAs and 171 DEmiRNAs were identified. Among the 4 lncRNAs common to the 3 datasets, prostate androgen‑regulated transcript 1 (PART1) was selected for further analysis. The analysis identified 5 DEmiRNAs and 13 DEmRNAs in the PART1‑mediated ceRNA network. The DEmRNAs in the ceRNA network were markedly enriched in cancer‑related biological processes (response to hypoxia, positive regulation of angiogenesis and positive regulation of endothelial cell proliferation) and pathways (cGMP‑PKG signaling pathway, cAMP signaling pathway and proteoglycans in cancer). Out of the 13 DEmRNAs, 11 were positively associated with PART1. The downregulation of PART1, myosin light chain 9 (MYL9), potassium calcium‑activated channel subfamily M alpha 1 (KCNMA1), cholinergic receptor muscarinic 1 (CHRM1), solute carrier family 25 member 4 (SLC25A4) and ATPase Na+/K+ transporting subunit alpha 2 (ATP1A2) expression levels in gastric cancer was validated by RT‑qPCR. On the whole, the current study identified a novel lncRNA and associated miRNAs and mRNAs that are involved in the pathogenesis of gastric cancer that may serve as potential therapeutic targets for the treatment of gastric cancer.

References

1 

Overman MJ: Immunotherapy in colorectal cancer with mismatch repair deficiency. Clin Adv Hematol Oncol. 17:265–267. 2019.PubMed/NCBI

2 

Shariq OA, Hanson KT, McKenna NP, Kelley SR, Dozois EJ, Lightner AL, Mathis KL and Habermann EB: Does metabolic syndrome increase the risk of postoperative complications in patients undergoing colorectal cancer surgery? Dis Colon Rectum. 62:849–858. 2019. View Article : Google Scholar : PubMed/NCBI

3 

Lund M, Trads M, Njor SH, Erichsen R and Andersen B: Quality indicators for screening colonoscopy and colonoscopist performance and the subsequent risk of interval colorectal cancer: A systematic review. JBI Database System Rev Implement Rep. Jun 18–2019.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI

4 

Kye BH, Rookkachart T, Kim JH, Kim HJ, Lee YS, Lee IK, Kang WK, Cho HM and Oh ST: Safety of laparoscopic oncologic resection in elderly patients with colorectal cancer: A multicenter retrospective study based on perioperative short-term outcomes. J Laparoendosc Adv Surg Tech A. Jun 12–2019.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI

5 

Kugimiya N, Harada E, Suehiro Y, Suga A, Takemoto Y and Hamano K: Determination of thymidine phosphorylase expression level facilitates recurrence risk stratification in stage II/III colorectal cancer following adjuvant chemotherapy with oral fluoropyrimidines. Oncol Lett. 17:5267–5274. 2019.PubMed/NCBI

6 

Long B, Xiao ZN, Shang LH, Pan BY and Chai J: Impact of perioperative transfusion in patients undergoing resection of colorectal cancer liver metastases: A population-based study. World J Clin Cases. 7:1093–1102. 2019. View Article : Google Scholar : PubMed/NCBI

7 

Kim MJ, Oh HK, Lee KC, Yang HH, Koo BW, Lee J, Kim MH, Kang SI, Kim DW and Kang SB: Effects of an Internet-based informational video on preoperative anxiety in patients with colorectal cancer. Ann Surg Treat Res. 96:290–295. 2019. View Article : Google Scholar : PubMed/NCBI

8 

Goto N, Fukuda A, Yamaga Y, Yoshikawa T, Maruno T, Maekawa H, Inamoto S, Kawada K, Sakai Y, Miyoshi H, et al: Lineage tracing and targeting of IL17RB+ tuft cell-like human colorectal cancer stem cells. Proc Natl Acad Sci USA. Jun 10–2019.(Epub ahead of print). View Article : Google Scholar

9 

Li K, Li L, Wu X, Yu J, Ma H, Zhang R, Li Y and Wang W: Loss of SDC1 expression is associated with poor prognosis of colorectal cancer patients in Northern China. Dis Markers. 2019:37687082019. View Article : Google Scholar : PubMed/NCBI

10 

Samarakoon YM, Gunawardena NS, Pathirana A, Perera MN and Hewage SA: Prediction of colorectal cancer risk among adults in a lower middle-income country. J Gastrointest Oncol. 10:445–452. 2019. View Article : Google Scholar : PubMed/NCBI

11 

Laghousi D, Jafari E, Nikbakht H, Nasiri B, Shamshirgaran M and Aminisani N: Gender differences in health-related quality of life among patients with colorectal cancer. J Gastrointest Oncol. 10:453–461. 2019. View Article : Google Scholar : PubMed/NCBI

12 

Midthun L, Shaheen S, Deisch J, Senthil M, Tsai J and Hsueh CT: Concomitant KRAS and BRAF mutations in colorectal cancer. J Gastrointest Oncol. 10:577–581. 2019. View Article : Google Scholar : PubMed/NCBI

13 

Taira K, Nadatani Y, Hirano S, Maeda K and Fujiwara Y: Large skin ulcer and delayed wound healing around a colostomy in a patient with metastatic colorectal cancer receiving vascular endothelial growth factor receptor-2 inhibitor therapy. Case Rep Oncol. 12:370–375. 2019. View Article : Google Scholar : PubMed/NCBI

14 

Amin M, Desai M, Trinkaus K, Brown A, Wang-Gillam A, Tan B, Picus J, Sorscher S, Highkin M, Lears K and Lockhart AC: Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer. J Gastrointest Oncol. 10:412–420. 2019. View Article : Google Scholar : PubMed/NCBI

15 

Aladhraei M, Al-Salami E, Poungvarin N and Suwannalert P: The roles of p53 and XPO1 on colorectal cancer progression in Yemeni patients. J Gastrointest Oncol. 10:437–444. 2019. View Article : Google Scholar : PubMed/NCBI

16 

Patel A, Tripathi G, McTernan P, Gopalakrishnan K, Ali O, Spector E, Williams N and Arasaradnam RP: Fibroblast growth factor 7 signalling is disrupted in colorectal cancer and is a potential marker of field cancerisation. J Gastrointest Oncol. 10:429–436. 2019. View Article : Google Scholar : PubMed/NCBI

17 

Vu JV, Matusko N, Hendren S, Regenbogen SE and Hardiman KM: Patient-reported unmet needs in colorectal cancer survivors after treatment for curative intent. Dis Colon Rectum. 62:815–822. 2019. View Article : Google Scholar : PubMed/NCBI

18 

Yang C, Wei C, Wang S, Shi D, Zhang C, Lin X, Dou R and Xiong B: Elevated CD163+/CD68+ ratio at tumor invasive front is closely associated with aggressive phenotype and poor prognosis in colorectal cancer. Int J Biol Sci. 15:984–998. 2019. View Article : Google Scholar : PubMed/NCBI

19 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

20 

Ling A, Lundberg IV, Eklöf V, Wikberg ML, Öberg Å, Edin S and Palmqvist R: The infiltration, and prognostic importance, of Th1 lymphocytes vary in molecular subgroups of colorectal cancer. J Pathol Clin Res. 2:21–31. 2015. View Article : Google Scholar : PubMed/NCBI

21 

Edelman EA and Reed EK: An update on risk assessment for familial and hereditary colorectal cancer. J Am Assoc Nurse Pract. 31:327–329. 2019.

22 

Li Q, Wei L, Lin S, Chen Y, Lin J and Peng J: Synergistic effect of kaempferol and 5-fluorouracil on the growth of colorectal cancer cells by regulating the PI3K/Akt signaling pathway. Mol Med Rep. May 27–2019.(Epub ahead of print).

23 

Dahal Lamichane B, Jung SY, Yun J, Kang S, Kim DY, Lamichane S, Kim YJ, Park JH, Jang WB, Ji ST, et al: AGR2 is a target of canonical Wnt/β-catenin signaling and is important for stemness maintenance in colorectal cancer stem cells. Biochem Biophys Res Commun. Jun 6–2019.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI

24 

Schmied BJ, Riegg F, Zekri L, Grosse-Hovest L, Bühring HJ, Jung G and Salih HR: An Fc-Optimized CD133 antibody for induction of natural killer cell reactivity against colorectal cancer. Cancers (Basel). 11:E7892019. View Article : Google Scholar : PubMed/NCBI

25 

Cheng D, Deng J, Zhang B, He X, Meng Z, Li G, Ye H, Zheng S, Wei L, Deng X, et al: LncRNA HOTAIR epigenetically suppresses miR-122 expression in hepatocellular carcinoma via DNA methylation. EBioMedicine. 36:159–170. 2018. View Article : Google Scholar : PubMed/NCBI

26 

Haddow JB, Walshe M, Aggarwal D, Thapar A, Hardman J, Wilson J, Oshowo A, Bhan C and Mukhtar H: Improving the diagnostic stage of the suspected colorectal cancer pathway: A quality improvement project. Healthc (Amst). 4:225–234. 2016. View Article : Google Scholar : PubMed/NCBI

27 

Aziz H, Pandit V, DiGiovanni RM, Ohlson E, Gruessner AC, Jandova J and Nfonsam VN: Increased incidence of early onset colorectal cancer in Arizona: A comprehensive 15-year analysis of the Arizona cancer registry. J Gastrointest Dig Syst. 5:3452015.PubMed/NCBI

28 

Guo LW, Li N, Chen HD, Lyu ZY, Feng XS, Wei LP, Li X, Wen Y, Lu M and Dai M: Progress in construction and verification of colorectal cancer risk prediction models: A systematic review. Zhonghua Yu Fang Yi Xue Za Zhi. 53:603–610. 2019.(In Chinese). PubMed/NCBI

29 

Nfonsam VN, Vijayasekaran A, Pandit V, E V, Aziz H, Nzuonkwelle S, Ohlson E, DiGiovanni RM and Jandova J: Patients diagnosed with colorectal cancer in rural areas in Arizona typically present with higher stage disease. J Gastrointest Dig Syst. 5(pii): 3462015.PubMed/NCBI

30 

Ciombor KK and Goldberg RM: Update on anti-angiogenesis therapy in colorectal cancer. Curr Colorectal Cancer Rep. 11:378–387. 2015. View Article : Google Scholar : PubMed/NCBI

31 

Dong-Xu W, Jia L and Su-Juan Z: MicroRNA-185 is a novel tumor suppressor by negatively modulating the Wnt/β-catenin pathway in human colorectal cancer. Indian J Cancer. 52 (Suppl 3):E182–E185. 2015. View Article : Google Scholar : PubMed/NCBI

32 

Du W and Fang JY: nutrients impact the pathogenesis and development of colorectal cancer. Gastrointest Tumors. 2:203–207. 2016. View Article : Google Scholar : PubMed/NCBI

33 

Wilder FG, Burnett A, Oliver J, Demyen MF and Chokshi RJ: A review of the long-term oncologic outcomes of robotic surgery versus laparoscopic surgery for colorectal cancer. Indian J Surg. 78:214–219. 2016. View Article : Google Scholar : PubMed/NCBI

34 

Raina K, Kumar S, Dhar D and Agarwal R: Silibinin and colorectal cancer chemoprevention: A comprehensive review on mechanisms and efficacy. J Biomed Res. 30:452–465. 2016.PubMed/NCBI

35 

Jia H, Xiang L, Wang Z and Zhou Q: A study on the mechanism of low-expressed cancer stem cell marker Lgr5 in inhibition of the proliferation and invasion of colorectal carcinoma. Cell Biochem Biophys. 73:393–397. 2015. View Article : Google Scholar : PubMed/NCBI

36 

Urbanska AM, Zhang X and Prakash S: Bioengineered colorectal cancer drugs: Orally delivered anti-inflammatory agents. Cell Biochem Biophys. 72:757–769. 2015. View Article : Google Scholar : PubMed/NCBI

37 

Ahronian LG and Corcoran RB: Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations. Mol Cell Oncol. 3:e10484052016. View Article : Google Scholar : PubMed/NCBI

38 

Sheng QS, Hua HJ, Cheng XB, Wang WB, Chen WB, Xu JH and Lin JJ: A modified spontaneously closed defunctioning tube ileostomy after anterior resection of the rectum for rectal cancer with a low colorectal anastomosis. Indian J Surg. 78:125–129. 2016. View Article : Google Scholar : PubMed/NCBI

39 

Han YH, Lim ST, Jeong HJ and Sohn MH: Clinical value of a one-stop-shop low-dose lung screening combined with (18)F-FDG PET/CT for the detection of metastatic lung nodules from colorectal cancer. Nucl Med Mol Imaging. 50:144–149. 2016. View Article : Google Scholar : PubMed/NCBI

40 

Triantafillidis JK, Vagianos C and Malgarinos G: Colonoscopy in colorectal cancer screening: Current aspects. Indian J Surg Oncol. 6:237–250. 2015. View Article : Google Scholar : PubMed/NCBI

41 

Dawood S, Sirohi B, Shrikhande SV, Toh HC and Eng C: Potential prognostic impact of baseline CEA level and surgery of primary tumor among patients with synchronous stage IV colorectal cancer: A large population based study. Indian J Surg Oncol. 6:198–206. 2015. View Article : Google Scholar : PubMed/NCBI

42 

Koelzer VH, Canonica K, Dawson H, Sokol L, Karamitopoulou-Diamantis E, Lugli A and Zlobec I: Phenotyping of tumor-associated macrophages in colorectal cancer: Impact on single cell invasion (tumor budding) and clinicopathological outcome. Oncoimmunology. 5:e11066772015. View Article : Google Scholar : PubMed/NCBI

43 

Correale P, Botta C, Martino EC, Ulivieri C, Battaglia G, Carfagno T, Rossetti MG, Fioravanti A, Guidelli GM, Cheleschi S, et al: Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients. Oncoimmunology. 5:e11012052015. View Article : Google Scholar : PubMed/NCBI

44 

Rosa I, Fidalgo P, Filipe B, Albuquerque C, Fonseca R, Chaves P and Pereira AD: Sporadic colorectal cancer: Studying ways to an end. United European Gastroenterol J. 4:288–296. 2016. View Article : Google Scholar : PubMed/NCBI

45 

Meyerhardt JA: What should we tell our patients with colorectal cancer about diet, supplements, and lifestyle? Clin Adv Hematol Oncol. 13:636–638. 2015.PubMed/NCBI

46 

Sun M, Geng D, Li S, Chen Z and Zhao W: LncRNA PART1 modulates toll-like receptor pathways to influence cell proliferation and apoptosis in prostate cancer cells. Biol Chem. 399:387–395. 2018. View Article : Google Scholar : PubMed/NCBI

47 

Angelova M, Charoentong P, Hackl H and Trajanoski Z: The colorectal cancer immune paradox revisited. Oncoimmunology. 5:e10780582015. View Article : Google Scholar : PubMed/NCBI

48 

Jurjus A, Eid A, Al Kattar S, Zeenny MN, Gerges-Geagea A, Haydar H, Hilal A, Oueidat D, Matar M, Tawilah J, et al: Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links. BBA Clin. 5:16–24. 2015. View Article : Google Scholar : PubMed/NCBI

49 

Sokolova EA, Boyarskikh UA, Shirshova AN, Kel AE and Filipenko ML: The biomarkers for timely diagnostics of colorectal cancer. Klin Lab Diagn. 60:15–23. 2015.(In Russian). PubMed/NCBI

50 

Echterdiek F, Janikovits J, Staffa L, Müller M, Lahrmann B, Frühschütz M, Hartog B, Nelius N, Benner A, Tariverdian M, et al: Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer. Oncoimmunology. 5:e10756922015. View Article : Google Scholar : PubMed/NCBI

51 

Russo G, Patrignani A, Poveda L, Hoehn F, Scholtka B, Schlapbach R and Garvin AM: Highly sensitive, non-invasive detection of colorectal cancer mutations using single molecule, third generation sequencing. Appl Transl Genom. 7:32–39. 2015. View Article : Google Scholar : PubMed/NCBI

52 

Stoll G, Zitvogel L and Kroemer G: Differences in the composition of the immune infiltrate in breast cancer, colorectal carcinoma, melanoma and non-small cell lung cancer: A microarray-based meta-analysis. Oncoimmunology. 5:e10677462015. View Article : Google Scholar : PubMed/NCBI

53 

Lu LL, Chen XH, Zhang G, Liu ZC, Wu N, Wang H, Qi YF, Wang HS, Cai SH and Du J: CCL21 facilitates chemoresistance and cancer stem cell-like properties of colorectal cancer cells through AKT/GSK-3β/Snail signals. Oxid Med Cell Longev. 2016:58741272016. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September 2019
Volume 20 Issue 3

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Gu, W., Ren, J., Zheng, X., Hu, X., & Hu, M. (2019). Comprehensive analysis of expression profiles of long non‑coding RNAs with associated ceRNA network involved in gastric cancer progression. Molecular Medicine Reports, 20, 2209-2218. https://doi.org/10.3892/mmr.2019.10478
MLA
Gu, W., Ren, J., Zheng, X., Hu, X., Hu, M."Comprehensive analysis of expression profiles of long non‑coding RNAs with associated ceRNA network involved in gastric cancer progression". Molecular Medicine Reports 20.3 (2019): 2209-2218.
Chicago
Gu, W., Ren, J., Zheng, X., Hu, X., Hu, M."Comprehensive analysis of expression profiles of long non‑coding RNAs with associated ceRNA network involved in gastric cancer progression". Molecular Medicine Reports 20, no. 3 (2019): 2209-2218. https://doi.org/10.3892/mmr.2019.10478